URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

ALNY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $37,273,899.08

Alnylam Pharmaceuticals Insider Trading History Chart

Alnylam Pharmaceuticals Share Price & Price History

^$245.44

▲ +6.57 (2.75%)

As of 12/20/2024 06:31 PM ET

Days: 30 | 90 | 365

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

Alnylam Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/12/2024	Pushkal Garg	CMO	Sell	1,752	$251.00	$439,752.00	15,705
11/26/2024	Pushkal Garg	CMO	Sell	1,682	$250.98	$422,148.36	17,457
11/26/2024	Tolga Tanguler	EVP	Sell	1,469	$250.98	$368,689.62	13,191
11/26/2024	Yvonne Greenstreet	CEO	Sell	5,219	$250.98	$1,309,864.62	78,880
8/20/2024	Yvonne Greenstreet	CEO	Sell	15,000	$280.00	$4,200,000.00	73,441
8/6/2024	Dennis A. Ausiello	Director	Sell	20,250	$262.00	$5,305,500.00	136
8/1/2024	Yvonne Greenstreet	CEO	Sell	15,148	$270.00	$4,089,960.00	73,441
7/11/2024	Yvonne Greenstreet	CEO	Sell	7,093	$261.00	$1,851,273.00	73,441
6/25/2024	Jeffrey V. Poulton	CFO	Sell	1,605	$231.00	$370,755.00	28,892
6/25/2024	Kevin Joseph Fitzgerald	EVP	Sell	1,198	$230.99	$276,726.02	14,181
6/25/2024	Pushkal Garg	CMO	Sell	2,103	$230.99	$485,771.97	15,609
6/25/2024	Yvonne Greenstreet	CEO	Sell	8,301	$230.99	$1,917,447.99	80,534
6/24/2024	David E. I. Pyott	Director	Sell	32,450	$220.69	$7,161,390.50	136
5/29/2024	Amy W. Schulman	Director	Sell	21,700	$148.60	$3,224,620.00	8,436
12/27/2023	Michael W. Bonney	Director	Sell	30,000	$195.00	$5,850,000.00	16,029
8/7/2023	Pushkal Garg	CMO	Sell	4,166	$183.89	$766,085.74	4,345
8/4/2023	Jeffrey V. Poulton	CFO	Sell	3,460	$185.85	$643,041.00	15,873
8/4/2023	Pushkal Garg	CMO	Sell	3,461	$185.85	$643,226.85	8,511
8/4/2023	Yvonne Greenstreet	CEO	Sell	4,057	$185.85	$753,993.45	35,216
4/27/2023	Akshay Vaishnaw	President	Sell	2,392	$194.59	$465,459.28	17,890
4/27/2023	Jeffrey V. Poulton	CFO	Sell	977	$194.59	$190,114.43	11,706
4/27/2023	Pushkal Garg	CMO	Sell	1,839	$194.59	$357,851.01	6,800
4/27/2023	Tolga Tanguler	EVP	Sell	1,476	$194.59	$287,214.84	1,801
4/27/2023	Yvonne Greenstreet	CEO	Sell	7,615	$194.59	$1,481,802.85	30,332
4/6/2023	Indrani Lall Franchini	EVP	Sell	3,500	$210.00	$735,000.00
3/3/2023	Pushkal Garg	CMO	Sell	18,072	$200.00	$3,614,400.00	4,345
2/2/2023	Indrani Lall Franchini	EVP	Sell	1,675	$226.01	$378,566.75	3,500
8/5/2022	Tolga Tanguler	EVP	Sell	1,841	$218.16	$401,632.56
8/3/2022	Tolga Tanguler	EVP	Sell	1,754	$210.00	$368,340.00	3,629
7/5/2022	Tolga Tanguler	EVP	Sell	1,754	$150.00	$263,100.00	1,754
4/1/2022	Steven M. Paul	Director	Sell	15,000	$170.69	$2,560,350.00	1,000
12/23/2021	Akshay Vaishnaw	Insider	Sell	2,879	$190.93	$549,687.47

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

SEC Filings (Institutional Ownership Changes) for Alnylam Pharmaceuticals (NASDAQ:ALNY)

92.97% of Alnylam Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Alnylam Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/19/2024	Principal Financial Group Inc.	10,608	$2.92M	0.0%	-25.2%	0.008%
11/29/2024	American Trust	1,123	$0.31M	0.0%	N/A	0.001%
11/25/2024	Tidal Investments LLC	20,544	$5.65M	0.1%	+75.1%	0.016%
11/25/2024	Sanctuary Advisors LLC	4,558	$1.25M	0.0%	+91.8%	0.004%
11/18/2024	Teachers Retirement System of The State of Kentucky	34,713	$9.55M	0.1%	+4.5%	0.027%
11/18/2024	Toronto Dominion Bank	15,466	$4.25M	0.0%	+27.3%	0.012%
11/18/2024	Coldstream Capital Management Inc.	1,211	$0.33M	0.0%	+43.7%	0.001%
11/18/2024	Orion Capital Management LLC	3,425	$0.94M	0.5%	-4.2%	0.003%
11/16/2024	Geode Capital Management LLC	2,147,203	$589.21M	0.0%	+3.2%	1.665%
11/15/2024	Prestige Wealth Management Group LLC	451	$0.12M	0.0%	+65.8%	0.000%
11/15/2024	Vestcor Inc	2,458	$0.68M	0.0%	+20.6%	0.002%
11/15/2024	Public Employees Retirement System of Ohio	48,437	$13.32M	0.1%	-6.3%	0.038%
11/15/2024	Groupama Asset Managment	1,521,385	$0.42M	0.0%	-0.2%	1.180%
11/15/2024	Nomura Asset Management Co. Ltd.	85,445	$23.50M	0.1%	+7.8%	0.066%
11/15/2024	MML Investors Services LLC	3,086	$0.85M	0.0%	+5.7%	0.002%
11/15/2024	Orion Portfolio Solutions LLC	3,541	$0.97M	0.0%	+14.8%	0.003%
11/15/2024	EP Wealth Advisors LLC	732	$0.20M	0.0%	N/A	0.001%
11/15/2024	Kovitz Investment Group Partners LLC	2,431	$0.67M	0.0%	N/A	0.002%
11/15/2024	Worldquant Millennium Advisors LLC	58,520	$16.10M	0.1%	-54.8%	0.045%
11/15/2024	Two Sigma Advisers LP	103,100	$28.36M	0.1%	-60.1%	0.080%
11/15/2024	Sphera Funds Management LTD.	7,000	$1.93M	0.3%	N/A	0.005%
11/15/2024	Stifel Financial Corp	5,830	$1.60M	0.0%	-1.8%	0.005%
11/15/2024	SYM FINANCIAL Corp	947	$0.26M	0.0%	+6.2%	0.001%
11/15/2024	Quantinno Capital Management LP	3,366	$0.93M	0.0%	+50.3%	0.003%
11/15/2024	Royal London Asset Management Ltd.	279,750	$76.94M	0.2%	-0.9%	0.217%
11/15/2024	Polar Asset Management Partners Inc.	5,900	$1.62M	0.0%	-41.0%	0.005%
11/15/2024	Parkman Healthcare Partners LLC	25,485	$7.01M	0.9%	N/A	0.020%
11/15/2024	Motley Fool Asset Management LLC	1,760	$0.49M	0.0%	-6.9%	0.001%
11/15/2024	Ikarian Capital LLC	8,741	$2.40M	0.3%	N/A	0.007%
11/15/2024	Investment Management Corp of Ontario	7,059	$1.94M	0.0%	+153.5%	0.005%
11/15/2024	Janus Henderson Group PLC	219,337	$60.32M	0.0%	-12.1%	0.170%
11/15/2024	HighTower Advisors LLC	115,790	$31.93M	0.0%	-7.4%	0.090%
11/15/2024	HighVista Strategies LLC	1,551	$0.43M	0.1%	-40.4%	0.001%
11/15/2024	Beacon Investment Advisory Services Inc.	4,401	$1.21M	0.1%	-5.1%	0.003%
11/15/2024	Erste Asset Management GmbH	16,510	$4.54M	0.1%	N/A	0.013%
11/15/2024	True Wealth Design LLC	154	$42K	0.0%	+15,300.0%	0.000%
11/14/2024	Bellevue Group AG	809,095	$222.53M	3.6%	-12.0%	0.627%
11/14/2024	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	21,108	$5.81M	0.0%	-12.8%	0.016%
11/14/2024	PDT Partners LLC	3,484	$0.96M	0.1%	-75.6%	0.003%
11/14/2024	Eventide Asset Management LLC	224,333	$61.70M	1.1%	+157.9%	0.174%
11/14/2024	Captrust Financial Advisors	4,833	$1.33M	0.0%	+34.4%	0.004%
11/14/2024	Suvretta Capital Management LLC	13,824	$3.80M	0.1%	-63.3%	0.011%
11/14/2024	MetLife Investment Management LLC	7,318	$2.01M	0.0%	-1.9%	0.006%
11/14/2024	Blueshift Asset Management LLC	1,067	$0.29M	0.1%	N/A	0.001%
11/13/2024	Bridgewater Associates LP	2,002	$0.55M	0.0%	N/A	0.002%
11/13/2024	Freedom Investment Management Inc.	1,159	$0.32M	0.0%	-9.8%	0.001%
11/13/2024	Brooklyn Investment Group	413	$0.11M	0.0%	N/A	0.000%
11/13/2024	Quantbot Technologies LP	204	$56K	0.0%	+1,754.5%	0.000%
11/13/2024	Dai ichi Life Insurance Company Ltd	955	$0.26M	0.0%	-11.3%	0.001%
11/13/2024	The Manufacturers Life Insurance Company	191,382	$52.64M	0.0%	-41.8%	0.148%
11/13/2024	Horizon Kinetics Asset Management LLC	2,759	$0.76M	0.0%	-4.2%	0.002%
11/13/2024	Loomis Sayles & Co. L P	525,303	$144.47M	0.2%	-7.7%	0.407%
11/13/2024	Harvest Fund Management Co. Ltd	162	$45K	0.0%	N/A	0.000%
11/13/2024	Daiwa Securities Group Inc.	12,072	$3.32M	0.0%	+6.9%	0.009%
11/12/2024	Swedbank AB	53,729	$14.78M	0.0%	+160.3%	0.042%
11/12/2024	Penserra Capital Management LLC	2,413	$0.66M	0.0%	-77.7%	0.002%
11/12/2024	Algert Global LLC	9,825	$2.70M	0.1%	+401.3%	0.008%
11/12/2024	Cerity Partners LLC	13,019	$3.58M	0.0%	+133.6%	0.010%
11/12/2024	Telemark Asset Management LLC	100,000	$27.50M	2.8%	N/A	0.078%
11/12/2024	Eagle Asset Management Inc.	309,589	$85.89M	0.5%	+25.7%	0.240%
11/12/2024	Charles Schwab Investment Management Inc.	487,348	$134.04M	0.0%	+3.6%	0.378%
11/8/2024	Grandfield & Dodd LLC	1,224	$0.34M	0.0%	N/A	0.001%
11/8/2024	Advisors Asset Management Inc.	4,767	$1.31M	0.0%	+4.1%	0.004%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	73,320	$20.17M	0.1%	+22.4%	0.057%
11/8/2024	Commerce Bank	4,522	$1.24M	0.0%	-2.1%	0.004%
11/8/2024	PNC Financial Services Group Inc.	12,543	$3.45M	0.0%	+1.2%	0.010%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	3,279	$0.90M	0.0%	N/A	0.003%
11/8/2024	Banque Cantonale Vaudoise	5,560	$1.53M	0.1%	N/A	0.004%
11/8/2024	Spectrum Planning & Advisory Services Inc.	3,359	$0.92M	0.9%	-5.6%	0.003%
11/7/2024	Pathstone Holdings LLC	6,249	$1.72M	0.0%	+11.2%	0.005%
11/7/2024	Nixon Peabody Trust Co.	2,250	$0.62M	0.1%	-31.8%	0.002%
11/7/2024	LMR Partners LLP	67,489	$18.56M	0.1%	-39.2%	0.052%
11/7/2024	TrinityPoint Wealth LLC	728	$0.20M	0.0%	N/A	0.001%
11/7/2024	Gilbert & Cook Inc.	3,924	$1.08M	0.1%	-3.4%	0.003%
11/7/2024	Swiss National Bank	375,400	$103.25M	0.1%	+0.3%	0.291%
11/6/2024	Mutual of America Capital Management LLC	1,924	$0.53M	0.0%	+26.7%	0.001%
11/6/2024	Natixis Advisors LLC	10,002	$2.75M	0.0%	N/A	0.008%
11/6/2024	Empowered Funds LLC	7,064	$1.94M	0.0%	+315.0%	0.005%
11/6/2024	CIBC Asset Management Inc	4,483	$1.23M	0.0%	+5.5%	0.003%
11/6/2024	OneDigital Investment Advisors LLC	1,021	$0.28M	0.0%	N/A	0.001%
11/6/2024	Metis Global Partners LLC	4,380	$1.21M	0.0%	+47.2%	0.003%
11/6/2024	Zions Bancorporation N.A.	592	$0.16M	0.0%	+2,860.0%	0.000%
11/6/2024	Huntington National Bank	94	$26K	0.0%	+91.8%	0.000%
11/6/2024	Plato Investment Management Ltd	4,702	$1.29M	0.1%	+33.2%	0.004%
11/6/2024	Oppenheimer & Co. Inc.	1,906	$0.52M	0.0%	+11.1%	0.001%
11/5/2024	Souders Financial Advisors	3,353	$0.92M	0.1%	-4.5%	0.003%
11/5/2024	Victory Capital Management Inc.	42,909	$11.80M	0.0%	+10.9%	0.033%
11/5/2024	Sumitomo Mitsui Trust Group Inc.	278,241	$76.53M	0.1%	+0.5%	0.216%
11/5/2024	Baillie Gifford & Co.	4,887,000	$1.34B	1.0%	-19.0%	3.789%
11/5/2024	GSA Capital Partners LLP	2,860	$0.79M	0.1%	+55.3%	0.002%
11/4/2024	Los Angeles Capital Management LLC	137,017	$37.68M	0.2%	+11,433.4%	0.107%
11/4/2024	State of New Jersey Common Pension Fund D	47,433	$13.05M	0.1%	-2.1%	0.037%
11/2/2024	Covestor Ltd	457	$0.13M	0.1%	-41.1%	0.000%
11/1/2024	Proficio Capital Partners LLC	744	$0.21M	0.0%	-53.0%	0.001%
11/1/2024	Atria Investments Inc	3,145	$0.87M	0.0%	+78.9%	0.002%
11/1/2024	Lindbrook Capital LLC	570	$0.16M	0.0%	+11.1%	0.000%
11/1/2024	Assetmark Inc.	9,186	$2.53M	0.0%	+8.2%	0.007%
11/1/2024	Washington Trust Advisors Inc.	152	$42K	0.0%	N/A	0.000%
11/1/2024	Hollencrest Capital Management	105	$29K	0.0%	N/A	0.000%
11/1/2024	Capital Performance Advisors LLP	440	$0.12M	0.0%	N/A	0.000%

Data available starting January 2016

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $245.44

$235.93

$247.21

50 Day Range

MA: $263.83

$232.27

$300.55

52 Week Range

Now: $245.44

$141.98

$304.39

Volume

1,648,262 shs

Average Volume

861,361 shs

Market Capitalization

$31.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' top insider investors include:
Yvonne Greenstreet (CEO)
Jeffrey V Poulton (CFO)
Akshay Vaishnaw (President)
Pushkal Garg (CMO)
Michael W Bonney (Director)
Kevin Joseph Fitzgerald (EVP)
Tolga Tanguler (EVP)
Amy W Schulman (Director)
Indrani Lall Franchini (EVP)
David E I Pyott (Director)
Dennis A Ausiello (Director)
Learn More about top insider investors at Alnylam Pharmaceuticals.
Who are the major institutional investors of Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' top institutional shareholders include:
Baillie Gifford & Co. — 3.79%
Geode Capital Management LLC — 1.66%
Groupama Asset Managment — 1.18%
Bellevue Group AG — 0.63%
Loomis Sayles & Co. L P — 0.41%
Charles Schwab Investment Management Inc. — 0.38%
Learn More about top institutional investors of Alnylam Pharmaceuticals stock.
Which major investors are selling Alnylam Pharmaceuticals stock?: In the last quarter, ALNY stock was sold by these institutional investors:
New York State Common Retirement Fund
Baillie Gifford & Co.
Two Sigma Advisers LP
The Manufacturers Life Insurance Company
Bellevue Group AG
Assenagon Asset Management S.A.
Worldquant Millennium Advisors LLC
Citigroup Inc.
During the last year, company insiders that have sold Alnylam Pharmaceuticals company stock include:
Yvonne Greenstreet (CEO)
Jeffrey V Poulton (CFO)
Akshay Vaishnaw (President)
Pushkal Garg (CMO)
Michael W Bonney (Director)
Kevin Joseph Fitzgerald (EVP)
Tolga Tanguler (EVP)
Amy W Schulman (Director)
Indrani Lall Franchini (EVP)
Learn More investors selling Alnylam Pharmaceuticals stock.
Which major investors are buying Alnylam Pharmaceuticals stock?: In the previous quarter, ALNY stock was acquired by institutional investors including:
Eventide Asset Management LLC
Los Angeles Capital Management LLC
Parallax Volatility Advisers L.P.
Telemark Asset Management LLC
Geode Capital Management LLC
Eagle Asset Management Inc.
Barclays PLC
Swedbank AB